Boiron SA
PAR:BOI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
28.1
42.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Boiron SA
Boiron SA
Cost of Revenue
Boiron SA
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Boiron SA
PAR:BOI
|
Cost of Revenue
-€130.8m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Sanofi SA
PAR:SAN
|
Cost of Revenue
-€18.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ipsen SA
PAR:IPN
|
Cost of Revenue
-€618m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-7%
|
|
|
Vetoquinol SA
PAR:VETO
|
Cost of Revenue
-€275.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Virbac SA
PAR:VIRP
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Medincell SA
PAR:MEDCL
|
Cost of Revenue
-€2.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Boiron SA
Glance View
Boiron SA engages in the manufacturing and selling homeopathic medicines. The company is headquartered in Rontalon, Auvergne-Rhone-Alpes. The firm develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. The company also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
See Also
What is Boiron SA's Cost of Revenue?
Cost of Revenue
-130.8m
EUR
Based on the financial report for Jun 30, 2024, Boiron SA's Cost of Revenue amounts to -130.8m EUR.
What is Boiron SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
0%
Over the last year, the Cost of Revenue growth was 3%. The average annual Cost of Revenue growth rates for Boiron SA have been -5% over the past three years .
You don't have any saved screeners yet
